NeoGenomics (NEO) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains
March 1, 2016 7:01 AM ESTFT. MYERS, Fla., March 1, 2016 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2015.
Fourth Quarter 2015 Highlights:
25% growth in base(1) test volume 12% reduction in Avg. Cost-per-test in base(1) business Record Adjusted EBITDA(2) of $2.9 million (even with $2.1 million of FISH reductions) Adjusted Diluted EPS(2) of $0.05 per share and Diluted EPS of ($0.03) per shareFull Year 2015 Highlights:
25% growth... More